-transparent.png){kind=logo}
We previously provided evidence that atrial natriuretic factor (ANF) antagonizes angiotensin II-induced vascular contractility and angiotensin II-stimulated aldosterone production by isolated adrenal cells. To examine the importance of these effects in vivo, synthetic ANF (auriculin A) was administered intravenously (2 micrograms/kg bolus followed by 0.3 microgram/kg/min constant infusion) to conscious, unrestrained two-kidney, one-clip and one-kidney, one-clip rats on normal sodium intake and their sham-operated controls. The one-kidney, one-clip rats also were studied on a sodium-deficient diet. Mean blood pressure, plasma renin activity, and plasma aldosterone levels were measured before and after 60-minute infusion. In saralasin-responsive two-kidney, one-clip rats (n = 10), ANF administration reduced blood pressure (from 187 +/- 11 [SE] to 153 +/- 11 mm Hg; p less than 0.001) and plasma aldosterone levels (from 182 +/- 61 to 125 +/- 60 ng/dl; p less than 0.05), while plasma renin activity increased (from 59 +/- 16 to 82 +/- 20 ng/ml/hr; p less than 0.05). Lesser changes in blood pressure occurred in saralasin-nonresponsive two-kidney, one-clip rats (149 +/- 10 to 143 +/- 8 mm Hg; n = 5), sodium-replete one-kidney, one-clip rats (183 +/- 9 to 170 +/- 11 mm Hg; n = 9), two-kidney sham-operated rats (122 +/- 3 to 115 +/- 4 mm Hg; n = 8), and one-kidney sham-operated rats (117 +/- 3 to 112 +/- 3 mm Hg; n = 7). Control plasma renin and aldosterone levels were not elevated in these latter groups and did not change significantly with ANF administration. In sodium-depleted one-kidney, one-clip rats, which became saralasin responsive, ANF administration significantly reduced blood pressure (from 184 +/- 11 to 156 +/- 12 mm Hg; n = 8), plasma aldosterone levels (from 286 +/- 41 to 179 +/- 36 ng/dl), and plasma renin activity (from 69 +/- 19 to 44 +/- 13 ng/ml/hr).(ABSTRACT TRUNCATED AT 250 WORDS)
M Volpe, and
G Odell, and
H D Kleinert, and
F Müller, and
M J Camargo, and
J H Laragh, and
T Maack, and
E D Vaughan, and
S A Atlas
January 1989,
Journal of cardiovascular pharmacology,
M Volpe, and
G Odell, and
H D Kleinert, and
F Müller, and
M J Camargo, and
J H Laragh, and
T Maack, and
E D Vaughan, and
S A Atlas
June 1986,
Federation proceedings,
M Volpe, and
G Odell, and
H D Kleinert, and
F Müller, and
M J Camargo, and
J H Laragh, and
T Maack, and
E D Vaughan, and
S A Atlas
January 1988,
Clinical therapeutics,
M Volpe, and
G Odell, and
H D Kleinert, and
F Müller, and
M J Camargo, and
J H Laragh, and
T Maack, and
E D Vaughan, and
S A Atlas
October 1988,
Hypertension (Dallas, Tex. : 1979),
M Volpe, and
G Odell, and
H D Kleinert, and
F Müller, and
M J Camargo, and
J H Laragh, and
T Maack, and
E D Vaughan, and
S A Atlas
June 1989,
American journal of hypertension,
M Volpe, and
G Odell, and
H D Kleinert, and
F Müller, and
M J Camargo, and
J H Laragh, and
T Maack, and
E D Vaughan, and
S A Atlas
January 1994,
Clinical endocrinology,
M Volpe, and
G Odell, and
H D Kleinert, and
F Müller, and
M J Camargo, and
J H Laragh, and
T Maack, and
E D Vaughan, and
S A Atlas
December 1984,
The American journal of medicine,
M Volpe, and
G Odell, and
H D Kleinert, and
F Müller, and
M J Camargo, and
J H Laragh, and
T Maack, and
E D Vaughan, and
S A Atlas
November 1985,
The New England journal of medicine,
M Volpe, and
G Odell, and
H D Kleinert, and
F Müller, and
M J Camargo, and
J H Laragh, and
T Maack, and
E D Vaughan, and
S A Atlas
February 1990,
Endocrinologia japonica,
M Volpe, and
G Odell, and
H D Kleinert, and
F Müller, and
M J Camargo, and
J H Laragh, and
T Maack, and
E D Vaughan, and
S A Atlas
April 1991,
Journal of human hypertension,
